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a b s t r a c t
'No-reﬂow' phenomenon is a common occurrence in percutaneous coronary intervention
(PCI). A three-component 'MAP strategy' was designed to prevent no-reﬂow by addressing
both intralesional and intraluminal thrombus in patients with ST-segment elevation myo-
cardial infarction (STEMI). In this analysis, we observed Thrombolysis In Myocardial Infarc-
tion (TIMI) ﬂow grade 3 or 2 in all patients, with no incidence of no-reﬂow. Myocardial blush
grade (MBG) 3 or 2 was observed in most (87.32%) patients. Left ventricular ejection fraction
(LVEF) was improved, without any incidence of death up to 9-month follow-up. All patients
safely tolerated the strategy-driven prolonged, 35-s inﬂation of the balloon/stent.
# 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India.
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Several thrombotic complications accompany percutaneous
coronary intervention (PCI), one of which is the no-reﬂow
phenomenon, deﬁned as inadequate myocardial perfusion* Corresponding author.
E-mail address: parisoha2013@gmail.com (A. Potdar).
http://dx.doi.org/10.1016/j.ihj.2015.11.014
0019-4832/# 2016 Published by Elsevier B.V. on behalf of Cardiologicawithout any evidence of mechanical obstruction in a sufﬁ-
ciently dilated coronary vessel. No-reﬂow is associated with
poor outcomes and a novel 'MAP strategy' was designed to
prevent it. 'MAP' implies (i) Maximum aspiration of athero-
thrombus, (ii) Adjuvant utilization of GP IIb/IIIa inhibitor, and
(iii) Prolonged inﬂation of the balloon/stent. This study is al Society of India.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 3 – s 4 6S44retrospective analysis of 71 cases, who underwent 'MAP'-
guided PCI for ST-segment elevation myocardial infarction
(STEMI), between February 2008 and January 2009.
2. Methods
2.1. Patient population
The study group belonged to three clinical subsets – primary
PCI (PPCI), deﬁned as angioplasty without prior or concomi-
tant ﬁbrinolytic therapy [performed within 12 h of STEMI];
pharmacoinvasive PCI, performed with a pharmacological
reperfusion treatment delivered prior to the planned PCI in
order to bridge the PCI-related time delay [PCI performed
within 24 h of STEMI]; and third, patients with ongoing
chest pain and nonresolution of ST-segment elevation (STE)
despite ﬁbrinolytic therapy, who were referred to the center
more than 24 h after STEMI [PCI performed within 72 h of
STEMI].
Inclusion criteria were (i) ST elevation of >2 mm in ≥2
consecutive leads, and (ii) presentation to the catheteriza-
tion lab within 24 h [for subset one and two], or within 72 h
[for subset three] of STEMI. Exclusion criteria were (i)
duration of presentation >72 h, (ii) left main coronary artery
thrombosis, (iii) TIMI grade 3 ﬂow on initial angiogram,
(iv) extensive triple-vessel disease, and (v) heavily calciﬁed
lesion.
2.2. Thrombus aspiration, pharmacotherapy, and stent
implantation
PCI was performed using standard techniques; femoral
approach was used. A loading dose of clopidogrel (300 mg)
and aspirin (350 mg) was administered on admission. Unfrac-
tionated heparin (100 units/kg) and tiroﬁban bolus (0.4 mg/kg/
min) for 30 min, followed by an infusion (0.15 mg/kg/min) for
12 h, were administered during the procedure.
Multiple passes (minimum two) of thrombus aspiration
were carried out, using a 6F thrombuster aspiration catheter
(Kaneka Medix, Japan) or 6F Export aspiration catheter
(Medtronic, Danvers, USA) (Fig. 1). Predilatation was carriedFig. 1 – Aspirated clot hanging freout if needed by inﬂating the balloon quickly till disappearance
of the waist, keeping it inﬂated at 1–2 atm higher for 35 s, and
later deﬂating it quickly. The balloon diameter was 0.5 mm
less than the vessel diameter. Stents lesser than 20 mm in
length were deployed at 14–18 atm. When residual stenosis
was ≥20%, or when stents of ≥20 mm length were used,
postdilatation with 10–12 mm length balloon was carried out
at 14–18 atm. Prolonged (35-s) inﬂation of stent was done only
in case of direct stenting.
2.3. Measurement of endpoints
Patients' angiographic (TIMI ﬂow grade and MBG), electrocar-
diographic (ECG), echocardiographic (LVEF), and clinical
assessments were done. Previous deﬁnitions of TIMI ﬂow
grade1 and MBG2were used. A 12-lead electrocardiogram (ECG)
was recorded just before, 6 h after, and 24 h after, the
procedure. Two-dimensional echocardiography was per-
formed prior to the procedure, at the time of discharge, and
at 9-month follow-up. Follow-up data were obtained at the end
of 1, 3, and 9 months after the procedure.
3. Results
The mean [SD] patient age was 58.3  12.0 years. Most
patients belonged to either the primary [31 (43.66%) patients]
or the pharmacoinvasive [33 (46.48%) patients] subsets. The
mean door-to-balloon time in PPCI was 290 min.
Following the 'MAP strategy', no patient showed TIMI grade
0 or 1 ﬂow (no-reﬂow) (Table 1). Successful reperfusion (MBG 3
or 2) and signiﬁcant STE recovery (>50% ST-segment resolu-
tion (STR)) were achieved in 62 (87.32%) and 51 (71.83%)
patients, respectively (Table 2). The mean (SD) LVEF
measured by two-dimensional echocardiography improved
by 6.76–50.56% (8.68%) at 9-month follow-up.
Two patients had minor dissections during aspiration,
which were tackled by the stent. Other than a case of
congestive cardiac failure after 6 months, no complications,
such as reinfarction, and angina requiring revascularization at
months 1, 3, and 9, were reported. Neither death nor
rehospitalization was reported up to the 9-month follow-up.e from aspiration catheter tip.
Table 1 – TIMI flow grades pre- and post-PCI.
Type of PCI Pre-PCI TIMI ﬂow grade Post-PCI TIMI ﬂow grade
Number of patients [n (%)] Number of patients [n (%)]
TIMI 2 TIMI 3
Primary TIMI 0 13 (41.94) 2 (6.45) 11 (35.48)
TIMI 1 11 (35.48) – 11 (35.48)
TIMI 2 7 (22.58) – 7 (22.59)
Total 31 (100) 2 (6.45) 29 (93.55)
Pharmacoinvasive TIMI 0 1 (3.03) – 1 (3.04)
TIMI 1 17 (51.52) 2 (6.06) 15 (45.45)
TIMI 2 15 (45.45) – 15 (45.45)
Total 33 (100) 2 (6.06) 31 (93.94)
Symptomatic patients up to 72 ha TIMI 0 5(71.43) 4 (57.14) 1 (14.29)
TIMI 1 2 (28.57) – 2 (28.57)
TIMI 2 – – –
Total 7 (100) 4 (57.14) 3 (42.86)
All TIMI 0 19 (26.76) 6 (8.45) 13 (18.31)
TIMI 1 30 (42.25) 2 (2.82) 28 (39.44)
TIMI 2 22 (30.99) – 22 (30.98)
Total 71 (100) 8 (11.27) 63 (88.73)
PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction.
a These patients were referred to the study center more than 24 h after STEMI, with failed thrombolysis. PCI was done within 72 h.
Table 2 – TIMI flow grades and ST-segment resolution based on grouped myocardial blush grades.





ST resolution >50% ST resolution ≤50%
0 or 1 9 (12.68) 7 (9.86) 2 (2.82) 5 (7.04) 4 (5.63)
3 or 2 62 (87.32) 1 (1.41) 61 (85.91) 46 (64.79) 16 (22.54)
MBG = myocardial blush grade; PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 3 – s 4 6 S454. Discussion
4.1. 'M': Maximum aspiration
No complications, such as stroke, coronary perforation,
or thrombus dislodgement, were reported in this study.
Notwithstanding the sample size and study design, the
death rate at 9 months in the present study (no death) was at
least numerically lower to that observed at 12 months
in the aspiration arm of the TAPAS3 study (3.6%). The
incidence of partial STR in the present study [51 (72%)
patients] too is similar to the EXPIRA4 trial (63% patients).
TIMI grade 3 ﬂow in 89% cases is comparable to
the incidence of TIMI grade 3 ﬂow in 86% cases in the
TAPAS3 trial.
4.2. 'A': Adjunctive glycoprotein IIb/IIIa inhibitors
Previous ﬁndings of positive associations5–9 with glycoprotein
IIb/IIIa inhibitors are congruent with our results in that up to 9
months after the PCI, no death, reinfarction, or target vessel
revascularization was reported. Furthermore, none of the
subjects in the present study encountered any major bleeding
episode.4.3. 'P': Prolonged balloon inﬂation
While thrombus aspiration acts on the intraluminal thrombus,
glycoprotein IIb/IIIa inhibitors act at the microvascular level.
Effectively, the ﬁrst two components ('M' and 'A') address
intraluminal and microvascular thrombus. It is postulated that
the third component ('P') addresses intralesional thrombus.
Rapid balloon inﬂation and deﬂation abruptly disrupts and
fragments the atheromatous material and results in distal
microembolization, as well as platelet activation, contributing
to acute occlusion. On the contrary, it is speculated that
the prolonged inﬂation possibly compresses the intralesional
plaque against the arterial wall and entraps it under the stent
struts, thus leading to reduced intravascular as well as
intracapillary thrombus burden.
5. Limitations
First, the sample was small and belonged to a single center,
and may not accurately represent diverse cases. Second, the
'MAP strategy' was not compared with a control group, which
makes it difﬁcult to state whether the observed favorable
outcomes were superior, equivalent, or inferior to PCI alone.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 3 – s 4 6S46Third, the analysis was retrospective, and could be confound-
ed by several variables. Lastly, complex patients were not
included.
6. Key messages
 The most interesting aspect of the 'MAP strategy' was that it
resulted in zero cases of TIMI ﬂow grade 0 or 1 ('no-reﬂow').
 The 'MAP strategy' is technically feasible and safe to
implement in day-to-day practice.
 Addition of a simple step of prolonged inﬂation can improve
angiographic and clinical outcomes; however, this concept
needs to be tested in large, controlled studies.
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